A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination With Intravenous Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nelitolimod (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms (PERIO)-01; PERIO-01
- Sponsors TriSalus Life Sciences
- 15 Aug 2024 According to a TriSalus Life Sciences media release, final results for the PERIO-01 Phase 1 trial are expected in Q4 2024.
- 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2023 Results presented in a MD Anderson Cancer Center Media Release.